Here's What to Expect From Moderna's Next Earnings Report

Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company is valued at $79.9 billion by market cap. The pharmaceutical and biotechnology company is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Friday, Nov. 6.

Ahead of the event, analysts expect Moderna to report a loss of $1.10 per share on a diluted basis, down 115.7% from $0.51 per share in the year-ago quarter. The company has consistently surpassed or met Wall Street’s bottom-line estimates in its last four quarterly reports. 

For the full year, analysts expect Moderna to report loss per share of $6.11, up 15.8% from $7.26 in fiscal 2025. Its loss per share is expected to recover 25.9% year over year to $4.53 in fiscal 2027. 

MRNA stock has significantly outperformed the S&P 500 Index’s ($SPX) 13.1% gains over the past 52 weeks, with shares up 662.3% during this period. Similarly, it massively outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 22.8% returns over the same time frame.

Moderna's dramatic outperformance over the past year has been fueled by massive momentum in its oncology pipeline, highlighted by landmark Phase 3 trial data for its individualized neoantigen therapy (intismeran autogene) combined with Merck & Co., Inc.’s (MRK) KEYTRUDA in melanoma, alongside broader validation from new product approvals like its mRNA flu vaccine, mFLUSIVA, and excitement surrounding a proposed U.S. public-private initiative to fast-track cancer vaccine development.

Analysts’ consensus opinion on MRNA stock is cautious, with a “Hold” rating overall. Out of 23 analysts covering the stock, four advise a “Strong Buy” rating, 16 give a “Hold,” and three recommend a “Strong Sell.” While MRNA currently trades above its mean price target of $133.24, the Street-high price target of $236 suggests an upside potential of 17.9%.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.